...测MS4A6A异常为手段的肿瘤诊断、预测预后方法;及激活MS4A6A基因或蛋白质的肿瘤治疗剂。背景技术多发性骨髓瘤(multiple myeloma)是血液系统的一种较常见的恶性肿瘤,它是由于机体的浆细胞异常克隆性增生的疾病,起源于B淋巴细胞,患者的骨髓内有浆细胞(或称为...
基于8979个网页-相关网页
...测MS4A6A异常为手段的肿瘤诊断、预测预后方法;及激活MS4A6A基因或蛋白质的肿瘤治疗剂。技术介绍多发性骨髓瘤(multiple myeloma)是血液系统的一种较常见的恶性肿瘤,它是由于机体的浆细胞异常克隆性增生的疾病,起源于B淋巴细胞,患者的骨髓内有浆细胞(或称为...
基于496个网页-相关网页
senile multiple myeloma 老年人多发性骨髓瘤
multiple myeloma related nephropathy 多发性骨髓瘤病肾病
indolent multiple myeloma 惰性骨髓瘤
multiple myeloma nephropathy 骨髓瘤肾病 ; 称为骨髓瘤肾病 ; 统称骨髓瘤肾病 ; 了解骨髓瘤肾病
MM multiple myeloma 多发性骨髓瘤
multiple myeloma cell 多发性骨髓瘤细胞
multiple myeloma cells 多发性骨髓瘤细胞
Q: When you first developed symptoms of multiple myeloma, you were disappointed to find that available research was not very helpful in deciding what to do.
问:当你最早发现自己出现多发性骨髓瘤症状时,却失望地发现现有研究对如何治疗的决定并无多大帮助。
The researchers deployed a combination of peptides—small pieces of protein—that are known to be specific to multiple myeloma cells and are important for their survival.
这些研究人员将肽(蛋白质片段)化合物作为研究重点,该化合物为多发性骨髓瘤细胞所独有,对于这种细胞的生存至关重要。
George Vlasuk, chief executive of Sirtris, said in a phone interview that the complication is common in multiple myeloma patients and "may or may not be related to" the drug.
Sirtris的首席执行官George Vlasuk在一个电话采访中说并发症对于多发性骨髓瘤很普遍,“可能会也可能不会”是和药物有关。
应用推荐